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bjectives We sought to compare outcomes in ST-segment elevation myocardial infarction (STEMI)
atients undergoing primary percutaneous coronary intervention (PCI) with or without previous cor-
nary artery bypass grafts (CABG).
ackground Limited information exists regarding procedural success and clinical outcomes of
TEMI patients with CABG undergoing primary PCI.
ethods The APEX-AMI (Assessment of Pexelizumab in Acute Myocardial Infarction) trial was a ran-
omized, placebo-controlled trial of pexelizumab in STEMI patients with planned primary PCI: 128 of
,745 (2.2%) patients had prior CABG. Clinical/procedural characteristics, culprit vessel (infarct-related
rtery [IRA]), and 90-day clinical outcomes were compared.
esults Patients with previous CABG were more frequently men, older, had a higher incidence of co-
orbidities and multivessel disease. In patients with versus without prior CABG, PCI was performed less
requently, that is, 78.9% versus 93.9%; of those with prior CABG receiving PCI, Thrombolysis In Myocar-
ial Infarction (TIMI) ﬂow grade 3 was also restored less often, that is, 82.5% versus 91.6% (both p 
.001). In prior CABG, there was a nearly even designation of the IRA as a bypass graft (n  63) versus a
ative vessel (n  55): IRA post-PCI TIMI ﬂow grade 3 was achieved in 66.7% versus 88.0%, respectively
p  0.043). Prior CABG patients had increased 90-day death and composite 90-day death/congestive
eart failure/shock. Excess death remained signiﬁcant after multivariable adjustment (hazard ratio: 1.9,
5% conﬁdence interval: 1.08 to 3.33, p  0.025). When prior CABG patients were stratiﬁed by the type
f IRA, there was further discrimination of the increased 90-day death, that is, 19% bypass graft (n  63)
ersus 5.7% native vessel (n  55, p  0.05), respectively.
onclusions Prior CABG patients with STEMI are less likely to undergo acute reperfusion, have
orse angiographic outcomes following primary PCI, and higher 90-day mortality. These ﬁndings are
specially applicable when the IRA was a bypass graft. (J Am Coll Cardiol Intv 2010;3:343–51)
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344espite increased use of secondary prevention measures, the
rogression of native coronary atherosclerosis and acceler-
ted atherosclerosis in saphenous vein grafts remains prob-
ematic. Attrition in these grafts occurs at a rate of at least
% to 5% yearly (1–5). Commensurate with these phenom-
na and the aging population there is an increase in the
umber of patients with prior coronary artery bypass graft-
ng (CABG) suffering acute ST-segment elevation myocar-
ial infarction (STEMI).
Despite this, limited information exists concerning these
atient outcomes following reperfusion therapy, and they are
requently excluded from clinical trials. Available evidence
uggests that fibrinolytic therapy may be less effective in this
opulation (6). This may relate in part to their increased age,
revalence of comorbidities, diminished left ventricular func-
ion, overall magnitude of atherosclerosis, and the impact of
egenerative vein grafts as culprit vessels (7). Although timely
xpert primary percutaneous coronary intervention (PCI) is the
referred strategy for STEMI patients, current guidelines are
conspicuously silent and do not
provide specific recommendations
on the optimal reperfusion strategy
in patients with prior CABG (8,9).
Furthermore, data describing
the prevalence of bypass graft
versus native coronary vessel as
the culprit infarct-related artery
(IRA) and the likelihood of an-
giographic success after primary
PCI is limited. To address these
issues, we examined the out-
comes of STEMI patients with a
past history of CABG in the
APEX-AMI (Assessment of
Pexelizumab in Acute Myocar-
ial Infarction) trial (10), a large trial of primary PCI in
TEMI patients (10).
ethods
atients. The entry criteria and main results for the APEX-
MI trial have been described previously (10). Enrollment
egan on July 13, 2004, and ended on May 11, 2006, which
esulted in a final population of 5,745 patients from 296
articipating hospitals in 17 countries. Enrollment criteria were
18 years old, within 6 h of symptom onset, and “high-risk”
lectrocardiograms (ECGs) qualified by fulfilling any of the
ollowing 3 criteria: 1) 2 mm of ST-segment elevation in 2
nterior or lateral leads; 2) 2 mm of ST-segment elevation in 2
nferior leads coupled with ST-segment depression in 2 con-
iguous anterior leads for a total ST-segment deviation of 8
m; or 3) new left bundle-branch block with at least 1 mm of
oncordant ST-segment elevation. They were expected to
bbreviations
nd Acronyms
ABG  coronary artery
ypass grafting
HF  congestive heart
ailure
CG  electrocardiogram
RA  infarct-related artery
CI  percutaneous
oronary intervention
T-E  ST-segment elevation
TEMI  ST-segment
levation myocardial
nfarctionndergo primary PCI, and there was no exclusion for prior pABG. No treatment difference attributable to pexelizumab
as observed; therefore, for the current analysis, randomized
reatment groups were combined.
nd points. Prospectively identified end points included 90-
ay death and the 90-day composite of death, centrally
djudicated congestive heart failure (CHF), or cardiogenic
hock. Briefly, CHF included new or worsening CHF that
egan or persisted 24 h after randomization or rehospitaliza-
ion for CHF. Cardiogenic shock was defined as hypotension
90 mm Hg systolic blood pressure) that lasted for at least
h, was not responsive to fluid resuscitation and/or heart rate
orrection, was believed to be secondary to cardiac dysfunction,
nd was associated with hypoperfusion.
CG analysis. The electrocardiograms were evaluated cen-
rally at the ECG core laboratories (Canadian VIGOUR
entre, Edmonton, Alberta, Canada, and Duke Clinical
esearch Institute, Durham, North Carolina) without
nowledge of patient characteristics, treatment assignment,
rocedural results, or clinical outcomes. ST-segment eleva-
ion sums (ST-E) were calculated as follows: for anterior
nfarction, the sum of ST-E in V1 to V6, I, and aVL; for
nferior infarction, the sum of ST-E in leads II, III, aVF,
5, and V6. ST-segment deviation sums were calculated by
dding the sum of ST-segment depression measured in
eciprocal leads to ST-E. Leads II, III, and aVF were
onsidered potential reciprocal leads for anterior infarctions,
nd leads V1 through V4 were considered potential recip-
ocal leads for inferior infarctions. Single-lead ST-E recov-
ry (percent reduction in ST-E from baseline to post-PCI
CG in the lead with maximum baseline ST-E) was
nalyzed in 2 categories (50%, 50%).
ngiographic analysis. Site investigators completed the an-
iographic analysis on all enrolled patients blinded to study
reatment. This included: determination of the culprit
oronary vessel (left main, left anterior descending, circum-
ex, right coronary artery, or bypass graft), documentation
f severity of coronary artery disease (1- vs. 2- vs. 3-vessel
isease), and determination of Thrombolysis In Myocardial
nfarction (TIMI) flow grade before and after PCI.
ardiac biomarkers. Biomarkers of myocardial necrosis (i.e.,
eak samples of creatine kinase [U/l], creatine kinase-
yocardial band [g/l], troponin I [g/l], or troponin T
g/l]) were collected and processed according to local
rotocols. Values were transformed into a ratio by dividing
he local patient value (in U/l or g/l) by upper limit of
ormal for that laboratory. Combined peak biomarkers’
pper limit of normal was constructed by using a hierarchy
f taking creatine kinase first, if missing then creatine
inase-myocardial band, if missing then troponin I, or if
issing then troponin T.
tatistical analysis. Data were reported as percentages for
iscrete variables and continuous variables as medians with
5th and 75th percentiles with chi-square tests and non-
arametric (Mann-Whitney or Kruskal-Wallis) tests for
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345Table 1. Selected Baseline Characteristics, In-Hospital Procedures, and Medications According to Prior CABG Status
No Prior CABG Prior CABG p Value
Baseline characteristics
n 5,617 128
Age, yrs, median (IQR) 61 (52.0–71.0) 69 (58.3–76.0) 0.001
Women, n (%) 1,306 (23.3) 18 (14.1) 0.014
Hypertension, n (%) 2,749 (49.0) 90 (70.3) 0.001
Prior myocardial infarction, n (%) 612 (10.9) 82 (64.1) 0.001
Prior PCI, n (%) 881 (9.2) 32 (36.7) 0.001
Prior CHF, n (%) 187 (3.3) 21 (16.4) 0.001
Diabetes mellitus, n (%) 187 (15.7) 32 (25.0) 0.007
Heart rate, beats/min, median (IQR) 75 (65.0–86.0) 75 (65.0–85.0) 0.405
Systolic BP, mm Hg, median (IQR) 133 (117.0–150.0) 135 (115.0–154.0) 0.586
Killip class I, n (%) 595 (10.6) 16 (12.5) 0.492
Noninferior myocardial infarction, n (%) 3,287 (59.9) 66 (53.2) 0.139
Symptom onset to randomization (min), median (IQR) 166 (119.0–237.0) 167.5 (120.5–269.3) 0.439
Randomization to PCI (min), median (IQR) 30 (21.0–43.0) 37 (28.0–55.0) 0.001
In-hospital procedures, %
Repeat PCI 7.0 4.7 0.317
Cardiac surgery 3.6 3.1 0.790
Mechanical ventilation 3.8 4.7 0.619
Permanent pacemaker 0.8 1.6 0.378
AICD 0.4 3.9 0.001
IABP 7.7 9.4 0.483
LVAD 0.4 1.6 0.05
Dialysis 0.5 0.8 0.604
Medications, %
Aspirin
Prior to randomization 69.6 85.2 0.001
Within 24 h of hospitalization 97.0 96.1 0.750
Discharge 94.5 87.5 0.002
Thienopyridine 25.6 24.2 0.716
Prior to randomization
In-hospital 92.8 85.9 0.003
Discharge 87.8 76.6 0.001
Both aspirin and thienopyridine in-hospital 91.3 83.6 0.003
GPI during index hospitalization 69.5 65.6 0.334
GPI prior to cardiac catheterization (among all GPI) 71.8 65.5 0.221
Beta-blocker
Prior to randomization 34.6 63.3 0.001
In-hospital 84.8 82.0 0.628
Discharge 83.7 82.8 0.212
Statin 19.0 60.9
Prior to randomization 0.001
In-hospital 91.0 91.4 0.946
Discharge 91.3 82.8 0.003
ACE inhibitor 18.6 35.9 0.001
Prior to randomization
In-hospital 79.5 71.9 0.095
Discharge 77.3 68.0 0.039
ACE  angiotensin-converting enzyme; AICD  automatic implantable cardioverter-defibrillator; BP  blood pressure; CABG  coronary artery
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346ifferences among groups. Kaplan-Meier survival estimates
ere used to compare time to the first occurrence of death
r the composite of death, CHF, or shock after random-
zation according to prior CABG status, with pairwise
ifferences tested using the log-rank test. To account for
ther baseline confounders of these associations, multivari-
ble models were developed using Cox proportional hazards
egression and adjusted hazard ratios and corresponding
5% confidence intervals for prior CABG status are re-
orted. Covariates considered in these models included age,
iabetes, systolic blood pressure, heart rate, Killip class, MI
ocation, ST-segment deviation on the admission ECG
or 90-day death and age, sex, prior MI, diabetes, systolic
lood pressure, heart rate, Killip class, ST-segment devi-
tion on the admission ECG for 90-day death/CHF/shock.
All hypotheses were determined a priori and as such no
djustments were made for multiple comparisons (i.e., all
ests were 2-sided, with a 5% level of significance). All
nalyses were performed with SAS statistical software (ver-
ion 9.1.3, SAS Institute, Cary, North Carolina).
esults
total of 5,745 patients were enrolled in APEX-AMI. Of
he total, 128 patients (2.2%) had a prior CABG in which
he infarct-related culprit vessel was determined to be a
ypass graft in 63 and a native coronary artery in 55 (IRA
as not discernible in 10) patients.
In Table 1, baseline characteristics, in-hospital proce-
ures, and medication use of the study population compar-
ng the 128 patients with prior CABG to those without
rior CABG are presented. Those with prior CABG were
Table 2. ECG Analysis and Peak Cardiac BM Accordi
n
Baseline ST-segment elevation, mm, median (IQR)
Baseline ST-segment deviation, mm, median (IQR)




Peak CK ULN, median (IQR)
n (peak CK-MB)
Peak CK-MB ULN, median (IQR)
n (peak TnI)
Peak TnI ULN, median (IQR)
n (peak TnT)
Peak TnT ULN, median (IQR)
n (combined BM)
Combined peak BM ULN, median (IQR)
BM biomarkers; CK creatine kinase; CK-MB creatine kinase-myoULN upper limit of normal; other abbreviations as in Table 1.lder, more likely to be men, and had more comorbidities
ncluding a history of hypertension, MI, PCI, CHF, and
iabetes mellitus. The time from randomization to PCI was
odestly delayed (median: 7 min) in those with prior
ABG. Consistent with the known diagnosis of coronary
rtery disease, those with prior CABG had a higher use of
vidence-based medications at the time of presentation.
espite this, at the time of discharge, evidence-based
edical therapies were used less frequently than in those
ithout prior CABG (Table 1). Of patients enrolled in
orth America, 3.2% had prior CABG, a higher percentage
han the 1.8% outside of North America.
Although their overall risk profile was higher, as seen in
able 2, the extent (sum) of baseline ST-segment elevation
nd deviation was lower in those with prior CABG. There
as a trend to achieving less ST-segment elevation resolu-
ion in the prior CABG group (50% resolution, 36.6% vs.
9.1%, p 0.093). Peak cardiac biomarkers were also lower
n the prior CABG patients.
Angiographic characteristics, revascularization proce-
ures, and 90-day clinical outcomes are presented in
able 3. Patients with prior CABG were more likely to have
ultivessel coronary artery disease and approximately half of
his group had a bypass graft identified as their IRA. Prior
ABG patients were less likely to undergo reperfusion, that
s, primary PCI was undertaken in only 78.9% of those with
ersus 93.9% (p  0.001) of those without prior CABG.
rgent CABG within 24 h was infrequent and similar
etween the 2 groups. Overall, 18.8% of those with prior
ABG received no acute reperfusion compared with 5.0%
n the comparison group (p  0.001). There was no
ifference in pre-PCI culprit artery TIMI flow grade be-
Prior CABG Status
Prior CABG Prior CABG p Value
5,617 128
(7.0–15.0) 7.5 (5.0–11.0) 0.001
(9.5–19.0) 11.0 (7.5–14.0) 0.001
(29.1) 41 (36.6) 0.093
(70.9) 71 (63.4)
4,272 91
(4.44–17.7) 5.38 (2.69–12.5) 0.001
2,193 60
(11.8–53.1) 17.5 (7.12–36.8) 0.004
2,953 72
(74.3–671.4) 178.8 (36.2–501.8) 0.065
1,437 24
(30.3–188.3) 50.1 (9.1–78.5) 0.010
5,250 114
(5.0–23.7) 7.6 (2.9–17.4) 0.001
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347ween those with versus without prior CABG. The use of
therectomy or thrombectomy devices was higher in the
rior CABG cohort (16.8% vs. 4.4%, p  0.001). Those in
he prior CABG cohort receiving primary PCI achieved
ower post-PCI TIMI flow grade 3 rates: 82.5% as com-
ared to 91.6% in the no prior CABG group (p  0.001).
Prior CABG patients were more likely to die within 90
ays (11.9% vs. 4.9%, p [log-rank] 0.001) (Fig. 1A) or
xperience death, CHF, or shock (16.4% vs. 10.1%, p
log-rank]  0.014) (Fig. 1B) compared to those without
rior CABG (Table 3). After multivariable adjustment,
rior CABG was significantly associated with a 90% relative
ncrease in the hazard of 90-day death (Fig. 2).
Investigators reported more operator-defined technical
imitations in prior CABG patients not receiving primary
Table 3. Angiographic, Revascularization Characteristics and 90-Day








Primary angiography, n (%) 5,602 (99.8) 127 (99.2) 0.182
Multivessel disease, n (%) 2,252 (40.2) 104 (81.9) 0.001
Culprit artery, n (%) 0.001
RCA 1,929 (34.3) 19 (15.2)
LCx 593 (10.6) 10 (8.0)
LAD 2,901 (51.6) 23 (18.4)
Left main 33 (0.6) 3 (2.4)
Graft 0 (0) 63 (50.4)
Unknown 28 (0.5) 3 (2.4)
None 101 (1.8) 4 (3.2)
Missing n 32 3
Pre-PCI TIMI ﬂow grade, n (%) 0.677
0/1 4,032 (73.8) 86 (77.5)
2 770 (14.1) 14 (12.6)
3 658 (12.1) 11 (9.9)
Primary PCI, n (%) 5,272 (93.9) 101 (78.9) 0.001
Use of atherectomy/thrombectomy, n (%) 234 (4.4) 17 (16.8) 0.001
Urgent (24 h symptom onset) cardiac surgery
(and did not undergo primary PCI), n (%)
60 (1.1) 3 (2.3) 0.165
No urgent revascularization (no urgent cardiac
surgery or primary PCI), n (%)
242 (5.0) 24 (18.8) 0.001
Post-PCI TIMI ﬂow grade, n (%) in those with
primary PCI
n 5,272 n 101 0.001
0/1 110 (2.1) 6 (6.2)
2 328 (6.3) 11 (11.3)
3 4,800 (91.6) 80 (82.5)
90-day clinical outcomes, n (%)
Death 256 (4.6) 15 (11.9) 0.001
CHF 267 (4.8) 8 (6.3) 0.4
Shock 188 (3.3) 8 (6.3) 0.082
Death/CHF/shock 565 (10.1) 21 (16.4) 0.019
LAD left anterior descending artery; LCx left circumflex artery; RCA right coronary artery;
TIMI Thrombolysis In Myocardial Infarction; other abbreviations as in Table 1.CI (Table 4). When these patients were compared withheir counterparts without prior CABG, who were also not
eceiving primary PCI, the prior CABG group had in-
reased 90-day clinical events (Table 4). Additionally, de-
pite higher baseline coronary perfusion (TIMI flow grade
: 29.4% [5 of 17] vs. 6.4% [6 of 94], p  0.012), prior
ABG patients not receiving primary PCI (n  27) had
ncreased 90-day events compared with prior CABG pa-
ients receiving primary PCI (n  101): 90-day death:
3.1% (6 of 27) versus 9.0% (9 of 101) (p  0.082), and
0-day death/CHF/shock: 25.9% (7 of 27) versus 13.9% (14
f 101) (p  0.149), respectively.
Selected baseline and post-randomization characteristics
re shown in Table 5 according to whether prior CABG
atients had their IRA identified as a bypass graft or native
oronary vessel. Despite similar (or better) pre-PCI TIMI
ow grade and a higher use of thrombectomy devices; those
ith a graft IRA had decreased post-PCI TIMI flow grade
Table 6). When the IRA was a bypass graft, 90-day clinical
vents were increased (Figs. 3A and 3B). After multivariable
djustment, there was no significant excess hazard of 90-day
eath or composite end point associated in CABG patients
ith a native vessel IRA compared with patients without
rior CABG (Fig. 4). However, in prior CABG patients
Figure 1. Kaplan-Meier Curves for 90-Day Clinical Outcomes
Kaplan-Meier curves for 90-day death according to prior coronary artery
bypass graft (CABG) (A) and for 90-day death/congestive heart failure
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348ith a bypass graft IRA, there was a significant 3-fold
ncrease in the hazard of 90-day death (Fig. 4).
iscussion
hese data from a large cohort of STEMI patients in
PEX-AMI provide new insights into the contemporary
revalence of prior CABG and its relationship to outcomes.
irst, STEMI patients with prior CABG exhibit a smaller
aseline territory at risk as measured by 12-lead ECG and
ess myocardial necrosis but have more frequent clinical
omorbidities and increased 90-day clinical events including
ortality. Second, those patients with prior CABG were
ess likely to receive urgent mechanical reperfusion; in fact,
1% did not receive their planned primary PCI. Those not
eceiving primary PCI were at particularly increased risk of
0-day clinical events when compared with other prior
Figure 2. Associations Between Prior CABG and 90-Day Clinical Outcomes
Unadjusted and adjusted associations between prior CABG status and 90-day c
Covariates used in the adjustment of 90-day death () included: age, diabetes
ST-segment deviation on the admission electrocardiogram (ECG); and for 90-
heart rate, Killip class, ST-segment deviation on the admission ECG. Abbrevia
Table 4. Investigator-Determined Reason for No Primary PCI, Initial TIMI
Flow Grade, and 90-Day Clinical Outcomes According to Prior
CABG Status
No Prior CABG Prior CABG p Value
n (no primary PCI) 342 27
Reasons provided by investigator, n (%)
No culprit lesion identiﬁed 112 (32.7) 9 (33.3)
Culprit lesion is patent 37 (10.8) 2 (7.4)
Technical limitations 82 (24.0) 10 (37.0)
Need for CABG 96 (28.1) 5 (18.5)
Catheterization not performed 12 (3.5) 1 (3.7)
Other 3 (0.1) —
Pre-PCI TIMI ﬂow grade 3, n (%) 112 (44.4) 5 (29.4) 0.313
90-day death, n (%) 29 (8.5) 6 (23.1) 0.028
90-day death/CHF/shock, n (%) 54 (15.8) 7 (25.9) 0.180Abbreviations as in Tables 1 and 3.ABG patients receiving primary PCI as well as that cohort
f patients without prior CABG who also did not receive
rimary PCI. Third, in those prior CABG STEMI patients
eceiving primary PCI, TIMI flow grade 3 was less fre-
uently achieved and ST-segment resolution was less com-
on. Of particular interest, among the prior CABG group
as the nearly equal distribution of the IRA between bypass
rafts and native coronary vessels. Although no obvious
l outcomes. Hazard ratios (HR) (95% conﬁdence intervals [CI]) are presented.
lic blood pressure, heart rate, Killip class, myocardial infarction (MI) location,
ath/CHF/shock (‘): age, sex, prior MI, diabetes, systolic blood pressure,
s in Figure 1.
Table 5. Selected Patient Characteristics According to Graft IRA Versus
Native IRA in Prior CABG Patients
IRA Graft Native IRA p Value
n 63 55
Age, yrs, median (IQR) 69 (60.0–76.0) 67 (56.0–83.4) 0.389
Women, n (%) 6 (9.5) 10 (18.2) 0.189
Hypertension, n (%) 44 (69.8) 36 (65.5) 0.694
Prior MI, n (%) 44 (69.8) 31 (56.4) 0.179
Prior PCI, n (%) 22 (34.9) 20 (36.4) 1.000
Prior CHF, n (%) 13 (20.6) 5 (9.1) 0.123
Diabetes mellitus, n (%) 19 (30.2) 9 (16.4) 0.088
Heart rate, beats/min, median
(IQR)
75 (60.0–83.0) 74 (65.0–85.0) 0.779
Systolic BP, mm Hg, median (IQR) 140 (115.0–158.0) 135 (121.0–153.0) 0.869
Killip class I, n (%) 8 (12.7) 7 (12.7) 1.000
Noninferior MI, n (%) 33 (55.0) 23 (42.6) 0.196
Symptom onset to randomization,
min, median (IQR)
173 (125.0–280.0) 156 (116.0–270.0) 0.426
Randomization to PCI, min,
median (IQR)
40 (24.5–64.5) 34 (29.0–48.0) 0.472
Both aspirin and thienopyridine
in-hospital
85.7% 85.5% 1.000
GPI during index hospitalization 77.8% 58.2% 0.022
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349ifferences in patient characteristics were evident between
hese groups, those with a bypass graft IRA had diminished
ost-PCI TIMI flow grade (despite increased use of throm-
ectomy/atherectomy devices) and increased risk of adverse
linical events.
Consistent with prior reports, those STEMI patients
ith prior CABG were older with an increased burden of
omorbidities (6,7,11–14). Despite this, and within the
onfines of a clinical trial with rigorous ECG entry criteria,
his group presented with less baseline ST-segment eleva-
ion (ST-E) and ST-segment deviation (ST-segment
eviation) suggesting a smaller myocardial territory at risk.
his is well aligned with the finding of less biomarker-
vident myocardial necrosis and prior evidence in STEMI
Table 6. Angiographic, ECG Measures, and 90-Day Clinical Outcomes in







Pre-PCI TIMI ﬂow grade, n (% valid) 0.020
0/1 41 (71.9) 43 (82.7)
2 12 (21.1) 2 (3.8)
3 4 (7.0) 7 (13.5)
Culprit artery, n (% valid)
RCA — 19 (34.5)
LCx — 10 (18.2)
LAD — 23 (41.8)
LM — 3 (5.5)
GLAD-LIMA 1 (1.6) —
GLAD-SVG 18 (29.0) —
GLCX-SVG 13 (21.0) —
GRCA-SVG 30 (48.4) —
Unknown 1 —
Atherectomy/thrombectomy, n/N (%) 13/53 (24.5) 4/47 (8.5) 0.060
Post-PCI TIMI ﬂow grade, n (% valid)
0/1 6 (12.0) 0 (0.0) 0.040
2 6 (12.0) 4 (8.7)
3 38 (76.0) 42 (91.3)
Baseline ST-segment elevation, mm,
median (IQR)
7.5 (4.6–11.4) 7.0 (5.0–11.0) 0.637
Baseline ST-segment deviation, mm,
median (IQR)
11.0 (8.0–15.3) 11.3 (7.0–13.6) 0.297
Single-lead ST-segment elevation
resolution, n (% valid)
50% 22 (40.0) 16 (32.0) 0.423
50% 33 (60.0) 34 (68.0)
n (peak combined BM ULN) 60 45
Peak combined BM ULN, median
(IQR)
10.6 (3.2–17.4) 7.3 (3.7–20.0) 0.912
90-day clinical outcomes, n (%)
Death 12 (19.0) 3 (5.7) 0.050
Death/CHF/shock 14 (22.2) 7 (12.7) 0.230
GLAD graft LAD; GLCX graft LCx; GRCA graft RCA; LIMA graft left internal mammary artery;
LM leftmain artery; SVG saphenous vein graft; other abbreviations as in Tables 1 to 3 and 5.atients with prior CABG receiving fibrinolysis (6). Theasis for this finding is unclear but could relate to the dual
irculation provided through native and bypass grafts and/or
ncreased presence of collateral blood vessels in conjunction
ith chronic severe coronary artery disease. It is also
ossible that the index STEMI occurred in a region with
rior MI.
It is notable in our study that 21% of prior CABG
TEMI patients with planned primary PCI failed to receive
eperfusion despite undergoing angiography whereas in
hose without prior CABG only 6.1% failed to receive
rimary PCI. The investigators cited the main reason for
ot proceeding with primary PCI as technical limitations
37%) followed by an inability to identify a culprit vessel
33%). There was no evidence of a protective effect of prior
ABG in patients that failed to receive primary PCI; in
act, the 90-day mortality in this group was 3 times greater
han those without prior CABG not receiving primary PCI
23.1% vs. 8.5%, p  0.028). Hence it seems probable that
Figure 3. Kaplan-Meier Curves for 90-Day Outcomes for No Prior CABG,
Prior CABG with Native IRA, and Prior CABG with Graft IRA Death
Kaplan-Meier curves for 90-day death according to prior CABG—graft ver-
sus native infarct-related artery (IRA) (A)—and for 90-day death/CHF/shock
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350his high-risk prior CABG patient cohort with STEMI for
hom primary PCI was planned failed to receive reperfu-
ion therapy due to the complexity of the IRA disease. This
ncidence of no acute reperfusion is of concern, and strate-
ies to optimize reperfusion in this group require further
ssessment.
Although the efficacy of reperfusion therapy is established
n STEMI patients, reperfusion success rates in patients
ith previous CABG is less well characterized. It has been
ostulated to be markedly reduced given the large amount of
therosclerotic material and thrombus burden with limited
unoff found in occluded saphenous vein grafts. Increased
ortality was shown in GUSTO-1 (Global Utilization of
treptokinase and TPA for Occluded Arteries I) trial (1990
o 1993) following reperfusion with tissue-type plasmino-
en activator where prior CABG patients (n  1,784) had
30-day mortality of 10.7% versus 6.7% in those without
rior CABG (n  39,147) (p  0.001) (6). The prior
ABG group in GUSTO-1 also had more pulmonary
dema, sustained hypotension, or cardiogenic shock and
orst angiographic outcomes achieving TIMI flow grade 3
ate of approximately 31% versus 49.2% in those without
rior CABG. These results are similar to those in the
urrent analysis from a study performed a decade later where
0-day mortality was 11.9% versus 4.6% for those with or
ithout prior CABG (p  0.001). In NRMI-2 (Second
ational Registry of Myocardial Infarction) database (n 
5,925), among the prior CABG STEMI patients that
eceived either tissue-type plasminogen activator (n  2,544)
r underwent primary PCI (n 375), there was no significant
ifference in the in-hospital clinical outcomes: in-hospital
ortality: 7.7% versus 8.0%, and death/nonfatal stroke: 8.6%
Figure 4. Associations Between Prior CABG Graft Versus Native IRA and 9
Unadjusted and adjusted associations between prior CABG status and native v
Covariates used in the adjustment of 90-day death () included: age, diabetes
on the admission ECG; and for 90-day death/CHF/shock (‘): age, sex, prior MI
on the admission ECG. Abbreviations as in Figures 1 to 3.ersus 8.5%, respectively (12). The optimal mode of reperfu- tion in the population of patients with prior CABG requires
urther systematic investigation.
Within the current analysis it appears the majority of risk
elated to prior CABG occurred in those in whom the
nterventional cardiologist deemed that the IRA was a
ypass graft. In fact, there was no difference in outcomes in
rior CABG patients with a native vessel IRA than in
atients without prior CABG. These results confirm prior
egistry data obtained from 1991 to 1997, based upon 128
rior CABG patients compared with 944 without prior
ABG with the culprit artery being a native vessel (n 65)
nd bypass graft (n  63) (15). After multivariate logistic
egression analysis correcting for baseline differences, prior
istory of CABG was not associated with adverse events but
reatment of bypass vein graft remained independently
ssociated with adverse cardiac events (relative risk: 1.48,
5% confidence interval: 1.07 to 2.03; p  0.02). This is
lso supported by a secondary analysis from PAMI-2
Second Primary Angioplasty in Myocardial Infarction
rial) study, which compared primary PCI bypass graft
n  32) to all patients with native coronary artery primary
CI (n  1,068); where in-hospital mortality was 9.4%
ersus 2.6%, respectively (p  0.02) (13). Mechanisms to
inimize adverse clinical events in patients with prior
ABG and bypass culprit IRA should be a priority of future
esearch.
tudy limitations. Within APEX-AMI, which had strict
2-lead ECG enrollment criteria, 2.2% of randomized
atients had prior CABG, which represented a selected
opulation. Multivariate adjustments may not be equally
ppropriate to both groups due to the difference in sample
ize between those with or without prior CABG. Although
Clinical Outcomes
graft IRA for 90-day clinical outcomes. Hazard ratios (95% CI) are presented.
lic blood pressure, heart rate, Killip class, MI location, ST-segment deviation
etes, systolic blood pressure, heart rate, Killip class, ST-segment deviation0-Day
ersus
, systo


























J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 3 , N O . 3 , 2 0 1 0 Welsh et al.
MA R C H 2 0 1 0 : 3 4 3 – 5 1 Prior Coronary Bypass and STEMI
351imited by the modest sample size. This is especially relevant
o the analysis of the IRA in the prior CABG group, which
hould be interpreted with caution.
onclusions
rior CABG patients with STEMI are less likely to
ndergo acute reperfusion, have worse angiographic out-
omes following primary PCI, and have higher 90-day
eath. These findings are especially applicable when the
RA was a bypass graft. Further investigation into the
anagement of this high-risk patient population is war-
anted and consensus clinical guidelines should address their
reatment.
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